HCPCS Code J9217: Leuprolide Acetate (Depot Suspension), 7.5 mg

Master billing for HCPCS code J9217. Our guide covers documentation, units, wastage, and administration codes for Leuprolide Acetate to ensure accurate claims.

Use Code

## **What is leuprolide acetate (depot suspension)?** J9217 reports leuprolide acetate for depot suspension at 7.5 mg per unit. Leuprolide is a gonadotropin-releasing hormone agonist that suppresses gonadal steroid production. A depot suspension is a long-acting, sustained-release formulation delivered by intramuscular or subcutaneous injection so the drug releases gradually over weeks. Brand examples include Lupron Depot monthly strengths, while other depot or implant formulations use different codes. Clinicians use leuprolide in therapy and treatment plans for prostate cancer and selected gynecologic conditions. Coverage policies may also reference epithelial ovarian cancer, fallopian tube carcinoma, or rare salivary gland tumors in defined settings. Per prescribing information, schedules vary by strength; monthly 7.5 mg is common. Some practices bill J9217 for Eligard because it is a leuprolide depot product; however, Eligard is a subcutaneous polymer depot, and payers often map it by NDC to a different leuprolide code set or require unit conversion rules that are not uniform. Prolia is denosumab rather than leuprolide; some people do bill J9217 for Prolia, but that substitution is incorrect and typically results in denials. It should be reported with its own code set, not J9217. Always follow the payer’s crosswalk before selecting a code.

## **J9217 documentation requirements** Capture enough detail to support medical necessity, units, and coverage. ### **Dose and unit calculation** Record the exact dose administered and convert to J9217 units: one unit per 7.5 mg. Include clear unit-conversion examples, such as 22.5 mg equals 3 units and 45 mg equals 6 units. Avoid math errors that misstate units on the claim. ### **Order and product identity** Maintain a signed provider order specifying leuprolide acetate for depot suspension. Document brand, strength, lot number, and expiration. Note the route as intramuscular or subcutaneous. ### **Diagnosis and indication** Link an appropriate diagnosis, such as prostate cancer, and state the clinical reason for use. The following indications commonly appear in payer language: prostate cancer, epithelial ovarian cancer, fallopian tube carcinoma, and salivary gland tumors when criteria are met. ### **Schedule and site of care** Document the planned interval, such as monthly for 7.5 mg, and the care setting. Include observation for injection reactions when the payer requires it. ### **Wastage and inventory** If a portion is discarded from a single-dose kit, document the discarded amount and report JW on a separate line. Use JZ to attest zero wastage when the entire container is administered.

## **J9217 billing requirements** Bill exactly what you administer and align with payer rules. ### **Units per 7.5 mg** Bill one unit for each 7.5 mg administered. Double-check conversions to prevent under- or over-billing. ### **Pair with the correct administration code** Use CPT 96402 as the chemotherapy administration code for subcutaneous or intramuscular hormonal antineoplastic therapy. Do not substitute a generic injection CPT code when payer policy specifies 96402. ### **Frequency and coverage** Confirm dose intervals and cumulative limits tied to coverage criteria. Medicare and commercial payers often require prior authorization for antineoplastic hormones within a chemotherapy plan. ### **Product mapping and brand selection** If the product dispensed is Eligard, follow the payer’s NDC-to-HCPCS mapping because some plans route Eligard differently than Lupron Depot despite pharmacologic similarity. If the product is Prolia (denosumab), do not use J9217 even if you have seen others do so; select the correct denosumab code set for a clean claim and to prevent rework. ### **Clean claim essentials** Include NDC when required, total units, diagnosis pointers, service date, and site of service. Ensure the chart supports medical necessity and route of administration.

## **J9217 applicable modifiers** Use only the modifiers your payer requires for drug lines: - **JW**: Report discarded amount from a single-dose container on a separate claim line. - **JZ**: Attest zero drug wastage when the entire single-dose container was administered. - **UD**: Program- or state-specific designation when a payer explicitly instructs its use. Modifiers for professional/technical split do not apply to J9217 drug lines. Apply them, when appropriate, to the related procedure CPT code.

## **Other relevant codes** Codes you may report with or instead of J9217. Verify active status and payer policy. - **96402**: Chemotherapy administration code for hormonal antineoplastic, intramuscular or subcutaneous. - **J9216**: Leuprolide acetate depot, 1 mg. - **J9218**: Leuprolide acetate, per 1 mg (non-depot formulation). - **J9225**: Leuprolide acetate implant, 11.25 mg. - **J9219**: Leuprolide acetate implant, 22.5 mg.

Frequently asked questions

Lupron Depot (leuprolide depot) is used for androgen deprivation in prostate cancer and for gynecologic indications such as endometriosis and uterine fibroids, according to prescribing information. It is also used in pediatrics for central precocious puberty when specialty criteria are met.

J9217 reports the depot, long-acting suspension at 7.5 mg per unit, and you convert the total dose to units. J9218 reports leuprolide acetate per 1 mg for non-depot formulations. Choose the code that matches the formulation and the dose description in the order.

J9217 is an HCPCS drug code, not a CPT code, and many plans require prior authorization for antineoplastic hormone therapy. Medicare Advantage and commercial payers may set step-therapy or coverage criteria tied to diagnosis. Attach supporting documentation to the claim.